PositiveSingles.com - the best, most trusted and largest anonymous STD dating site!

Herpes Survival Kit - a specially designed pack containing everything you need to combat herpes and cold sore outbreaks (at a minimum cost to your wallet).

only search Racoon.com

"The Good News about the Bad News - 
Herpes: Everything You Need to Know
"  
Terri Warren's new book - which we do endorse.

First time visitor? Please Learn about Registering and read our policy page.
{Home}{Awareness}{Research}{Treatment}{HHP FAQ}{Bookstore}{Bio/Info Page}

The Original Herpes Home Page Discussion Forums

Subject: "Aicuris confident about AIC316 therapeutic drug"     Previous Topic | Next Topic
Printer-friendly copy     Email this topic to a friend    
Conferences Herpes News Topic #1569
Reading Topic #1569
muffinadmin
Member since Sep-10-04
6230 posts
Jun-01-12, 04:10 AM (CST)
Click to EMail muffin Click to send private message to muffin Click to view user profileClick to add this user to your buddy list  
"Aicuris confident about AIC316 therapeutic drug"
 
http://www.aicuris.com/10d72/News_Publications.htm


Better prevention of transmission and lesion development of genital herpes predicted for AiCuris drug AIC316

16April2012


PRESS RELEASE

Better prevention of transmission and lesion development of genital herpes predicted for AiCuris drug AIC316

Data showing stronger reduction of clinically relevant viral shedding in comparison with nucleosides to be presented at upcoming conferences

Wuppertal, 16th April 2012 - AiCuris announced today that in depth analysis of data from the AIC316 Phase 2 trial in patients with genital herpes will be disclosed at several international meetings. This information adds to the very favourable efficacy data meeting the primary endpoint of the trial which have already been announced. It further highlights the superiority of AIC316 in the treatment of genital herpes.

The reduction of shedding of genital herpes simplex virus (HSV) by AIC316 in the recent Phase 2 trial will be compared with data from clinical trials with nucleoside analogues. AIC316, a HSV inhibitor with a novel mode of action and much improved half-life, shows superior reduction of shedding events associated with high viral load, which is regarded as clinically relevant for HSV lesion development and transmission.

AiCuris project leader Dr. Alexander Birkmann will present the data at the International Conference on Antiviral Research (ICAR) meeting in Sapporo, Japan, on 19th April 2012. Furthermore, Professor Helga Rübsamen-Schaeff, CEO of AiCuris, will give an invited talk on AIC316 discussing this topic at the International Herpesvirus Workshop in Calgary, Canada, 4th-9th August 2012.

"Encouraged by this data the planning and preparation of the Phase 3 program is now underway with high priority" comments Dr. Marie Paule Richard, CMO of AiCuris.


  Alert | IP Printer-friendly page | Edit | Reply | Reply With Quote | Top
Koolmom2008
Member since Apr-11-12
62 posts
Jun-01-12, 07:04 PM (CST)
Click to EMail Koolmom2008 Click to send private message to Koolmom2008 Click to view user profileClick to add this user to your buddy list  
1. "RE: Aicuris confident about AIC316 therapeutic drug"
In response to message #0
 
   Could this mean that the drug could stop the shedding dead in it's tracks? Thanks for posting the info.


  Alert | IP Printer-friendly page | Edit | Reply | Reply With Quote | Top
muffinadmin
Member since Sep-10-04
6230 posts
Jun-01-12, 11:10 PM (CST)
Click to EMail muffin Click to send private message to muffin Click to view user profileClick to add this user to your buddy list  
2. "RE: Aicuris confident about AIC316 therapeutic drug"
In response to message #1
 
That's not how I read this. It seems like it could be better at reducing shedding (than current antivirals) but not eliminate it completely.

Not sure how much this would in turn impact the transmission risk.

Phase III should help to learn more about how effective it might be.

muffin ~ GHSV1 since 1986


  Alert | IP Printer-friendly page | Edit | Reply | Reply With Quote | Top

Conferences | Topics | Previous Topic | Next Topic

 

Advertisements appearing on this page do not constitute any endorsement of 
those products or services by HHP or its management.

All opinions expressed here by the HHP, its management and participants constitute just that, opinions.
No medical relationship with any participant is implied in any way.
Each individual's personal doctor is responsible for the medical advice and care of that person.